Test in the hardest population
Relapsed/refractory and SoC samples are where differentiation is most meaningful. We benchmark your compound(s) against standard-of-care activity in those same cells.
Benchmark single-agent and combination activity in primary samples from patients with failure and relapsed/refractory disease — the population in which a new mechanism must demonstrate efficacy.
Relapsed/refractory and SoC samples are where differentiation is most meaningful. We benchmark your compound(s) against standard-of-care activity in those same cells.
Activity benchmarking
Single-agent and combination activity versus standard of care in resistant samples.
Resistance mapping
Patterns of cross-resistance and retained sensitivity across the drug panel.
Restoration data
Quantitative evidence of whether your asset restores sensitivity.
Genotype linkage (optional)
Pair with NGS to link resistance phenotype to genotype.
Resistant disease is the hardest test and the most persuasive proof — for go/no-go decisions, the salvage-combination rationale, and a differentiated development story.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
